UPB

Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.

Wall Street analysts forecast UPB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UPB is 57.50 USD with a low forecast of 40.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Upstream Bio Inc revenue for the last quarter amounts to 683.00K USD, increased 12.52 % YoY.

Upstream Bio Inc. EPS for the last quarter amounts to -0.63 USD, increased 53.66 % YoY.

Upstream Bio Inc (UPB) has 52 emplpoyees as of December 15 2025.

Today UPB has the market capitalization of 1.47B USD.